• Profile

Obesity care needs greater revolution: Report

IANS Jan 19, 2024

The development of new weight loss medicines by pharma companies Novo Nordisk and Eli Lilly have been making great progress, but obesity care needs a much greater revolution, according to a report on 18th Jan.

Novo Nordisk and Eli Lilly have been dominating the obesity drug market in the past year with the approval of their glucagon-like peptide-1 receptor (GLP-1R) agonists Wegovy and Zepbound.

Although medicines with other mechanisms of action are available on the market, GLP-1R agonists seem to have a greater impact on weight loss and the patient’s life.

The report by GlobalData, a data and analytics company, showed that diagnostic and management tools for obesity need to be updated and patients are not receiving the appropriate support from health authorities and insurance companies.

"Obesity was previously considered a lifestyle choice to be corrected with diet and exercise. In 2013, the American Medical Association (AMA) voted to recognise obesity as a chronic metabolic disease needing treatment and prevention efforts, but no implementations have been made for medical practice," said the Pharma Analyst at GlobalData, in a statement.

"There isn't a specific medical figure specialised in obesity yet, most doctors still don’t recognise obesity as a true disease and in most countries, a stronger network of obesity centres is missing to ensure patients are receiving the best possible care," she added.

Another issue in obesity management is the lack of accurate diagnostic methods, as the body mass index (BMI) is not considered to be accurate in many cases, according to a high-prescribers survey conducted by GlobalData in December 2023.

The survey included 151 prescribers from the US, Germany, France, Italy, Spain, the UK, and Japan.

"The BMI is calculated considering only the patient's height and weight, and it does not take into consideration the patient's body composition.

"Patients with a healthy-range BMI might have a very high percentage of fat tissue, and in that case, they would be unhealthier than a bodybuilder, for example, who has a higher BMI but whose body composition is mostly lean muscle mass.

"There are methods used to calculate body composition, for instance, bioelectrical impedance analysis (BIA) and DEXA scanning, and some physicians tend to use them in combination with BMI, but according to GlobalData’s high-prescribers survey, there is a need for more accurate and unified diagnostic criteria and methods for diagnosing obesity," she said.

The report also raised concerns regarding the need for reimbursement strategies for obesity patients.

In the US, the national insurance companies Medicaid and Medicare cover some obesity procedures and treatments, but only in some states.

In Europe, the situation is very heterogenous: in the UK, the National Health Service (NHS) is required to cover pharmacotherapy for obesity patients, while the German legislature does not differentiate obesity treatment from the recreational pursuit of weight loss for vanity purposes, and consequently, obesity medications are not covered by the national insurance.

This is a great limitation for obese patients, especially if we think about the price of GLP1R agonist treatment.

"Physicians' and public awareness of obesity as a chronic metabolic disease is still an unmet need in the healthcare sector," she said.

"Consequently, a lot of progress still needs to be made to ensure more efficient diagnosis, prevention, and treatment of obesity, including the implementation of wider coverage by national insurance companies on obesity medications and procedures. Obesity is frequently a socioeconomic issue, especially in the US, and the disparity in treatment access, as seen with GLP-1R agonists, only confirms that" she added.

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen